Abstract
BackgroundThe aim of this retrospective study was to highlight the role of FDG PET/CT in the assessment of tumor response to preoperative chemotherapy in pediatric sarcoma. Eighteen patients were included in our study: 13 patients were males and 5 were females ranging between 1 and 18 years with a mean age of 13.3 years. The patients had pathologically proven osseous or soft tissue sarcoma. All patients underwent sequential 18F-FDG PET/CT before (PET-CT1) and after (PET-CT2) neoadjuvant chemotherapy. Maximum standardized uptake value (SUVmax) was measured in the primary lesion on PET/CT1 (SUV1) and PET/CT2 (SUV2). After surgery, the effects of neoadjuvant chemotherapy were evaluated histopathologically: ≥ 90% necrosis indicated was considered a good response and < 90% necrosis was considered a poor response. The correlation between SUV2 and the histologic response was assessed.ResultsThe sensitivity, specificity, positive predictive value, and negative predictive value of SUV2 for assessment of treatment response were 100%, 91.67%, 85.71%, and 100%, respectively. The overall accuracy was found to be 98.3%.Conclusions18F-FDG PET/CT provides a reliable non-invasive diagnostic tool in assessment of response to preoperative chemotherapy in pediatric sarcoma.
Highlights
The aim of this retrospective study was to highlight the role of FDG PET/computed tomography (CT) in the assessment of tumor response to preoperative chemotherapy in pediatric sarcoma
FDG-18Ffluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) imaging is a noninvasive modality for restaging and assessment of treatment response of patients after sarcoma treatment and has been found to have a profound effect on overall prognosis [18]. The aim of this retrospective study was to highlight the role of FDG PET/CT in the assessment of therapy response in pediatric sarcoma
A total of 36 PET/CT studies were performed in 18 patients of our study: 13 patients were males (72.2%) and 5 patients were females (27.8%)
Summary
The aim of this retrospective study was to highlight the role of FDG PET/CT in the assessment of tumor response to preoperative chemotherapy in pediatric sarcoma. Pediatric sarcomas differ according to histologic subtype, but as a whole, represent about 13% of all pediatric malignancies [1]. Soft tissue sarcomas have wide range according to genetic makeup, have more than 50 histologic subtypes, and are often associated with differing clinical and prognostic features [2]. These tumors, which arise in the soft tissues namely muscle, fat, blood vessels, nerves, tendons, or synovium, On the other hand, the most common primary malignant bone tumors in pediatric age are osteosarcoma and Ewing sarcoma [3]. Ewing sarcoma originates from the axial and the appendicular skeleton [5]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Egyptian Journal of Radiology and Nuclear Medicine
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
